Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy

acute myeloid leukemia, fluoroquinolone, prophylaxis, induction chemotherapy
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

ConclusionRapid peripheral blast clearance after 7+3 induction demonstrated a significant improvement in specificity compared to D14BM, while maintaining similar sensitivity. Neither of these methods were reliably specific tools for the decision of early re-induction, despite their prognostic value. Our findings indicate that morphological cellularity in D14BM is an independent prognostic factor for OS and RFS, regardless of blast percentage, and that ≤10% cellularity defines D14BM hypoplasia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The presence of recurrent genetic mutations in the myeloblasts of patients with acute myeloid leukemia (AML) are prognostic and incorporated into risk stratification systems of both the National Comprehensive Cancer Network and European Leukemia Network.1 In patients with FLT3-internal tandem duplications (FLT3-ITD) or tyrosine kinase domain mutations (TKD) small molecule inhibitors of the resultant mutant proteins in combination with cytotoxic chemotherapy can improve overall survival in newly diagnosed AML patients with a FLT3 mutation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
ConclusionsThe rate of complete response after the first course of induction therapy was significantly higher among adult patients with AML who received IDA as a part of induction therapy compared with those who received HDD.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 17 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Wasithep Limvorapitak, Michael Barnett, Donna Hogge, Donna Forrest, Thomas Nevill, Sujaatha Narayanan, Maryse Power, Stephen Nantel, Raewyn Broady, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, Alina Gerrie, Jennifer White, David SanfordAbstract (245 word of 250 words recommended)IntroductionOptimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia (AML) remains an area of ongoing research. We aimed to retrospectively compare outcomes following autoSCT with allogeneic SCT (allo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. FallerAbstractAcute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly (≥60 years ol...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionElevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. FallerAbstractAcute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly (≥60 years ol...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionElevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Clinical trials in acute myeloid leukemia (AML) for the last 40 years have generally focussed on younger patients or older patients clinically judged to be fit for intensive chemotherapy. However the median age of AML is 68-70 years so there was a large “trial- neglected” population, for whom therapeutic options were not being explored. The standard of care was palliation with supportive care, and if necessary mild oral chemotherapy to control the white count, so called “Best Supportive Care” (BSC).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Leukemia | Lymphoma | Myeloma